Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Daiichi Sankyo
Farmers Insurance
Argus Health
Cerilliant
Dow
UBS
Cantor Fitzgerald
Mallinckrodt

Generated: December 11, 2018

DrugPatentWatch Database Preview

King Pfizer Company Profile

« Back to Dashboard

Summary for King Pfizer
International Patents:44
US Patents:1
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for King Pfizer

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
King Pfizer HUMATIN paromomycin sulfate CAPSULE;ORAL 062310-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
King Pfizer ALTACE ramipril TABLET;ORAL 022021-004 Feb 27, 2007 DISCN Yes No 7,368,469 ➤ Try a Free Trial ➤ Try a Free Trial
King Pfizer ALTACE ramipril TABLET;ORAL 022021-002 Feb 27, 2007 DISCN Yes No 7,368,469 ➤ Try a Free Trial ➤ Try a Free Trial
King Pfizer ALTACE ramipril TABLET;ORAL 022021-001 Feb 27, 2007 DISCN Yes No 7,368,469 ➤ Try a Free Trial ➤ Try a Free Trial
King Pfizer ALTACE ramipril TABLET;ORAL 022021-003 Feb 27, 2007 DISCN Yes No 7,368,469 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for King Pfizer

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
King Pfizer ALTACE ramipril TABLET;ORAL 022021-004 Feb 27, 2007 5,061,722 ➤ Try a Free Trial
King Pfizer ALTACE ramipril TABLET;ORAL 022021-001 Feb 27, 2007 5,061,722 ➤ Try a Free Trial
King Pfizer ALTACE ramipril TABLET;ORAL 022021-004 Feb 27, 2007 5,403,856 ➤ Try a Free Trial
King Pfizer ALTACE ramipril TABLET;ORAL 022021-003 Feb 27, 2007 5,403,856 ➤ Try a Free Trial
King Pfizer ALTACE ramipril TABLET;ORAL 022021-002 Feb 27, 2007 5,403,856 ➤ Try a Free Trial
King Pfizer ALTACE ramipril TABLET;ORAL 022021-003 Feb 27, 2007 5,061,722 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for King Pfizer Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB98/047 United Kingdom ➤ Try a Free Trial PRODUCT NAME: COMBINATIONS OF RAMIPRIL, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND FELODIPINE, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: SE 13596 19970919; SE 13597 19970919; UK 00017/0402 19980825; UK 00017/0403 19980825
80030 Netherlands ➤ Try a Free Trial PRODUCT NAME: FELODIPINE, DESGEWENST IN DE VORM VAN FYSIOLOGISCH AANVAARDBAAR ZOUT, EN (2S, 3AS, 6AS)-1-[(S)-N-[(S)-1-CARBOXY-3-FENYLPROPYL]A LANYL]OCTAHYDROCYCLOPENTA[B]-PYRROOL-2-CARBONZUUR (RAMIPRILAAT) , DESGEWENST IN DE VORM VAN EEN .....ZIE VERDER IN HET DOSSIER; NAT. REGISTRATION NO/ DATE: RVG 22449, RVG 22450 19980618; FIRST REGISTRATION: SE 13596, 13597 19970919
C0001 Belgium ➤ Try a Free Trial PRODUCT NAME: FELODIPINUM + RAMIPRILUM; NATL. REGISTRATION NO/DATE: 354 IS 373 F 3 19981103; FIRST REGISTRATION: SE 13597 19970919
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Daiichi Sankyo
Chinese Patent Office
Express Scripts
Argus Health
Healthtrust
Citi
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.